🟢 LTRN is trading 6.1% up today on renewed oncology pipeline interest and FDA trial progress

LTRN is trading at $4.17 (6.1% up) in pre-market, bouncing after recent volatility as interest returns to its oncology pipeline.

• Sentiment is supported by prior FDA IND clearance for STAR-001 and multiple orphan and fast-track designations across its clinical programs.
• The company's AI-driven cancer drug development story remains a focal point, though investors continue to weigh long-term potential against future funding needs and dilution risk.